[HTML][HTML] Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis
W Gao, L Sun, J Gai, Y Cao, S Zhang - Plos one, 2024 - journals.plos.org
Background The triple negative breast cancer (TNBC) is the most malignant subtype of
breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario …
breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario …
Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis
W Gao, L Sun, J Gai, Y Cao, S Zhang - PLoS ONE, 2024 - ui.adsabs.harvard.edu
Background The triple negative breast cancer (TNBC) is the most malignant subtype of
breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario …
breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario …
Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis
W Gao, L Sun, J Gai, Y Cao, S Zhang - Plos one, 2024 - europepmc.org
Background The triple negative breast cancer (TNBC) is the most malignant subtype of
breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario …
breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario …
Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis
W Gao, L Sun, J Gai, Y Cao, S Zhang - PloS one, 2024 - pubmed.ncbi.nlm.nih.gov
Background The triple negative breast cancer (TNBC) is the most malignant subtype of
breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario …
breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario …
[HTML][HTML] Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis
W Gao, L Sun, J Gai, Y Cao, S Zhang - PLOS ONE, 2024 - ncbi.nlm.nih.gov
Background The triple negative breast cancer (TNBC) is the most malignant subtype of
breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario …
breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario …
Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis.
W Gao, L Sun, J Gai, Y Cao, S Zhang - PLoS ONE, 2024 - search.ebscohost.com
Background: The triple negative breast cancer (TNBC) is the most malignant subtype of
breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario …
breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario …
Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis.
W Gao, L Sun, J Gai, Y Cao, S Zhang - PLoS ONE, 2024 - go.gale.com
Background The triple negative breast cancer (TNBC) is the most malignant subtype of
breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario …
breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario …
Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis.
W Gao, L Sun, J Gai, Y Cao, S Zhang - Plos one, 2024 - europepmc.org
The triple negative breast cancer (TNBC) is the most malignant subtype of breast cancer
with high aggressiveness. Although paclitaxel-based chemotherapy scenario present the …
with high aggressiveness. Although paclitaxel-based chemotherapy scenario present the …